M
M

Financials • Maze Therapeutics

MAZE

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

12/2022
3 financials
12/2024
Year
12/2022
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2023
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
168
61
52
31%
-311
L
-170
-
66
-1
93
65
0.08

To see all financials—including updated, you must be Premium.